186 filings
Page 4 of 10
EFFECT
dwz496db
6 Nov 20
Notice of effectiveness
12:15am
CORRESP
0q4 dxeg8f
3 Nov 20
Correspondence with SEC
12:00am
UPLOAD
6dcufy5dttn4dhlamho
29 Oct 20
Letter from SEC
12:00am
F-3
8lo8ooeda 0z3d
23 Oct 20
Shelf registration (foreign)
5:23pm
6-K
hfalurpz
21 Oct 20
Invitation to the Extraordinary Shareholders' Meeting
6:42am
6-K
2zb4arle
23 Sep 20
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
7:55am
6-K
tf94ia dc3uo
8 Sep 20
Current report (foreign)
5:17pm
424B5
9ss3zvspkk1cbpux
8 Sep 20
Prospectus supplement for primary offering
5:06pm
6-K
q960m6j
5 Aug 20
Current report (foreign)
7:29am
6-K
8aq4rs9wfxc32mw2
16 Jul 20
Current report (foreign)
8:25am
6-K
0tc tifk0llcomg62g
26 Jun 20
Current report (foreign)
4:51pm
6-K
r3c7whs70ojl7vvayfx
22 May 20
Invitation to the Ordinary Shareholders' Meeting
8:40am
6-K
yldb75n 1d
4 May 20
Current report (foreign)
8:32am
6-K
wk8iua e9j5
2 Apr 20
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
7:11am
6-K
n5cdjcfh91eg
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am
6-K
x74uk4vwfc9ckiycwv
23 Mar 20
AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership
8:15am
UPLOAD
43h6b37 5dwfh6pm
25 Feb 20
Letter from SEC
12:00am
CORRESP
6shp1 wp24mbyssa2yvi
17 Jan 20
Correspondence with SEC
12:00am
UPLOAD
tx0ay9pe1xzulb18se
6 Jan 20
Letter from SEC
12:00am